Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services...

Descripción completa

Detalles Bibliográficos
Autores principales: Weberpals, Janick, Roumpanis, Spyros, Barer, Yael, Ehrlich, Sharon, Jessop, Nikki, Pedotti, Rosetta, Vaknin-Dembinsky, Adi, Brill, Livnat, Chodick, Gabriel, Rouzic, Erwan Muros-Le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422340/
https://www.ncbi.nlm.nih.gov/pubmed/36081277
http://dx.doi.org/10.1016/j.msard.2022.104153
_version_ 1784777789873848320
author Weberpals, Janick
Roumpanis, Spyros
Barer, Yael
Ehrlich, Sharon
Jessop, Nikki
Pedotti, Rosetta
Vaknin-Dembinsky, Adi
Brill, Livnat
Chodick, Gabriel
Rouzic, Erwan Muros-Le
author_facet Weberpals, Janick
Roumpanis, Spyros
Barer, Yael
Ehrlich, Sharon
Jessop, Nikki
Pedotti, Rosetta
Vaknin-Dembinsky, Adi
Brill, Livnat
Chodick, Gabriel
Rouzic, Erwan Muros-Le
author_sort Weberpals, Janick
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.
format Online
Article
Text
id pubmed-9422340
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-94223402022-08-30 Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel Weberpals, Janick Roumpanis, Spyros Barer, Yael Ehrlich, Sharon Jessop, Nikki Pedotti, Rosetta Vaknin-Dembinsky, Adi Brill, Livnat Chodick, Gabriel Rouzic, Erwan Muros-Le Mult Scler Relat Disord Correspondence The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity. Elsevier B.V. 2022-12 2022-08-29 /pmc/articles/PMC9422340/ /pubmed/36081277 http://dx.doi.org/10.1016/j.msard.2022.104153 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Weberpals, Janick
Roumpanis, Spyros
Barer, Yael
Ehrlich, Sharon
Jessop, Nikki
Pedotti, Rosetta
Vaknin-Dembinsky, Adi
Brill, Livnat
Chodick, Gabriel
Rouzic, Erwan Muros-Le
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
title Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
title_full Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
title_fullStr Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
title_full_unstemmed Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
title_short Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
title_sort clinical outcomes of covid-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-sars-cov-2 vaccination periods: insights from israel
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422340/
https://www.ncbi.nlm.nih.gov/pubmed/36081277
http://dx.doi.org/10.1016/j.msard.2022.104153
work_keys_str_mv AT weberpalsjanick clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT roumpanisspyros clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT bareryael clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT ehrlichsharon clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT jessopnikki clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT pedottirosetta clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT vaknindembinskyadi clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT brilllivnat clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT chodickgabriel clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael
AT rouzicerwanmurosle clinicaloutcomesofcovid19inpatientswithmultiplesclerosistreatedwithocrelizumabinthepreandpostsarscov2vaccinationperiodsinsightsfromisrael

Ejemplares similares